Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Esomeprazole/naproxen - Old API Wind-down/AstraZeneca

Drug Profile

Esomeprazole/naproxen - Old API Wind-down/AstraZeneca

Alternative Names: esomeprazole magnesium trihydrate/naproxen; Naproxen/esomeprazole; naproxen/esomeprazole magnesium trihydrate; PN-400; Vimovo

Latest Information Update: 08 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca; Cincinnati Children's Hospital Medical Center; POZEN
  • Developer AstraZeneca; Horizon Pharma; Old API Wind-down Ltd
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Anti-inflammatories; Antirheumatics; Naphthaleneacetic acids; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Prostaglandin synthase inhibitors; Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Ankylosing spondylitis; Osteoarthritis; Rheumatoid arthritis
  • Clinical Phase Unknown Juvenile rheumatoid arthritis

Most Recent Events

  • 06 Feb 2019 Aralez Pharmaceuticals is now called Old API Wind-down
  • 31 Dec 2018 Nuvo Pharmaceuticals in-licenses esomeprazole/naproxen from Horizon Pharma and Grunenthal
  • 05 Dec 2018 Esomeprazole/naproxen licensed to Grünenthal for worldwide commercialisation except for in Japan and the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top